- First shipment of Khiron branded EU-GMP certified medical
cannabis to Germany successfully
completed, providing immediate access to German market through
distribution partner, Nimbus Health GmbH
- Launch product is Khiron 1/14 high-CBD flower, which will focus
on indications such as anxiety, substance use disorder, and
migraines, addressing patient needs and improving access to medical
cannabis
- Company to leverage partnership with Nimbus Health GmbH, a
leading EU-GMP/GDP certified medical cannabis distributor in
Germany with network of over 300
pharmacies
- Khiron teams continue to educate physicians with plans to
leverage clinical evidence from both the UK and Colombia
TORONTO, March 22, 2021 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that the
Company has successfully delivered EU-GMP medical cannabis product
to Germany. In collaboration with
Nimbus Health, a leading medical cannabis distributor in
Germany, Khiron is now positioned
for imminent first sales in Germany. Khiron products are currently in
inventory in the Nimbus warehouse, ready to be prescribed to
patients and distributed through a vast network of 300 pharmacies
across Germany.
This major milestone represents a new revenue stream for the
Company and positions Khiron's European team to execute on its
German medical strategy. Leveraging its partner's large
distribution network and Khiron's ongoing investments in physician
education, the Company has secured immediate access to the German
market. Khiron 1/14 will focus on indications such as anxiety,
substance use disorder, and migraines, addressing patient needs and
improving access to medical cannabis.
Tejinder Virk, President of
Khiron Europe, commented, "Since signing our distribution
agreement with Nimbus Health in 2020, the Company's European Sales
and Marketing teams have been actively educating doctors and
raising awareness for our products. We are excited to launch our
portfolio with Khiron 1/14, a product that covers unmet medical
need in the German market. As we continue to expand our presence in
the UK and Germany, we will
leverage our clinical expertise from Colombia to provide the EU market with
additional cannabis-based medicinal products."
Franziska Katterbach, Managing Director & Chief Legal
Officer for Khiron Europe based in Frankfurt, commented, "I would like to thank
our European team for their unwavering perseverance over the past
few months; their efforts have allowed us to achieve this
significant milestone despite the challenges of the global pandemic
and Germany's strict regulatory
environment. With all permits in place and product now available
for sale, we look forward to increasing our presence in this
growing market with over 60,000 medical cannabis patients and a
population of over 82 million people. We are already developing
additional cannabis-based medicinal products from our certified
strains recently imported from Colombia to improve access and product
selection for German patients."
Through its EU-GMP certified supply chain partners in
Europe, Khiron continues to expand
its offering of world-class medical cannabis products, targeting
the introduction of cannabis-based medicinal products based on
those already distributed by the Company in Colombia and Peru. With Khiron's proof of concept now
validated in Colombia, the Company
plans to leverage its clinical data and IP, educational platforms,
and technology and systems to expand into new markets.
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis
company with core operations in Latin
America, and operational activity in Europe and North
America. Khiron is the leading medical cannabis provider in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution and sales, and
international export of both low and high THC medical cannabis
products. The Company has filled medical cannabis prescriptions in
Colombia, Peru and the United
Kingdom, and is positioned to commence sales of medical
cannabis in Mexico, Germany and Brazil in 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with KuidaTM now marketed
in multiple jurisdictions in Latin
America, the US and United
Kingdom. The Company is led by Co-founder and Chief
Executive Officer, Alvaro Torres,
together with an experienced and diverse executive team and Board
of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-medical-cannabis-products-arrive-in-germany-for-immediate-prescription-sale-and-distribution-301251197.html
SOURCE Khiron Life Sciences Corp.